FDA Clearance Tracker · P140008-S019
ORBERA Intragastric Balloon System
Last checked: Nov 20, 2026Latest source record: Dec 2, 2020 (this decision)Source: openFDAMethods & limitations
Decided
Dec 2, 2020
Approved
Time to decision
177 days
Received Jun 8, 2020. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P140008-S019
- Device name
- ORBERA Intragastric Balloon System
- Applicant
- Boston Scientific Corporation
- Applicant location
- Marlboro, MA
- Received
- Jun 8, 2020
- Decided
- Dec 2, 2020
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Labeling Change - PAS
- Original approval
- P140008
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for the ORBERATM PAS (OPAS-001.0. The OPAS-001 is a prospective, open-label, single-arm study to evaluate the safety and effectiveness of ORBERA for weight reduction in obese adults 22 years and older with a BMI of 30-40 kg/m2. This is a 52-week study in which subjects will be treated during the first 26 weeks with ORBERA in conjunction with a behavioral modification program, followed by 26 weeks of behavioral modification program alone.A total of 284 subjects will be enrolled at 10 to 20 US sites to yield 255 subjects implanted with ORBERA (assuming a 10% screen failure rate). Based on an estimated attrition rate of 10% through week 26 and 20% through week 52, the expected number of evaluable subjects is 230 subjects at 26 weeks and 204 subjects at 52 weeks. A sample size of 255 implanted subjects will provide 80% power to test the hypothesis that the rate of device- and/or procedure-related serious adverse events (SAEs) is less than 15% at 26 weeks.
Source documents
Other decisions for Boston Scientific Corporation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- SpaceOAR Flex System510(k)
K262151 · Decided Sep 11, 2026 · 78 days after receipt
Device type: Hydrogel Spacer (OVB) · Radiology & Imaging
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.